Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Mammen to depart J&J, leaving behind data science foundation

Data science deals, expanded pipeline diversity define Mathai Mammen’s five years as pharmaceuticals R&D leader at J&J

By Lauren Martz, Executive Director, Biopharma Intelligence
August 8, 2022 11:07 PM UTC

Seven new drug approvals, more than 30 label expansions and a deal-driven foundation in data science define the legacy that Mathai Mammen leaves at J&J after serving more than five years as the pharma’s EVP of pharmaceutical R&D.

Johnson & Johnson (NYSE:JNJ) announced Mammen’s departure late Monday. William Hait will serve as interim head of the Pharmaceutical R&D organization until new leadership is found.  Mammen will remain at least through year end to aid with the transition. J&J is initiating a search for his replacement...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Amgen Inc.

Fate Therapeutics Inc.

Galapagos N.V.

Johnson & Johnson

Meiragtx Holdings plc

Mersana Therapeutics Inc.